Correlation Between AN2 Therapeutics and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both AN2 Therapeutics and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AN2 Therapeutics and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between AN2 Therapeutics and Inhibikase Therapeutics, you can compare the effects of market volatilities on AN2 Therapeutics and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AN2 Therapeutics with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of AN2 Therapeutics and Inhibikase Therapeutics.
Diversification Opportunities for AN2 Therapeutics and Inhibikase Therapeutics
0.39 | Correlation Coefficient |
Weak diversification
The 3 months correlation between AN2 and Inhibikase is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding AN2 Therapeutics and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and AN2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AN2 Therapeutics are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of AN2 Therapeutics i.e., AN2 Therapeutics and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between AN2 Therapeutics and Inhibikase Therapeutics
Given the investment horizon of 90 days AN2 Therapeutics is expected to generate 2.67 times less return on investment than Inhibikase Therapeutics. In addition to that, AN2 Therapeutics is 1.21 times more volatile than Inhibikase Therapeutics. It trades about 0.03 of its total potential returns per unit of risk. Inhibikase Therapeutics is currently generating about 0.09 per unit of volatility. If you would invest 182.00 in Inhibikase Therapeutics on September 2, 2024 and sell it today you would earn a total of 110.00 from holding Inhibikase Therapeutics or generate 60.44% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
AN2 Therapeutics vs. Inhibikase Therapeutics
Performance |
| Timeline |
| AN2 Therapeutics |
| Inhibikase Therapeutics |
AN2 Therapeutics and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with AN2 Therapeutics and Inhibikase Therapeutics
The main advantage of trading using opposite AN2 Therapeutics and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AN2 Therapeutics position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| AN2 Therapeutics vs. Tff Pharmaceuticals | AN2 Therapeutics vs. Eliem Therapeutics | AN2 Therapeutics vs. Inhibrx | AN2 Therapeutics vs. Enliven Therapeutics |
| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Complementary Tools
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |